Molecular Templates, Inc.
11 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Threshold Pharmaceuticals, Inc. (to 2018)
1
Ending by 2030
Jun 2030
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 27, 2027The maintenance fee for Multivalent CD20-Binding Molecules Comprising Shiga Toxin a Subunit Effector Regions and Enriched Compositions Thereof (US 10,392,425) comes due Feb 27, 2027. Unpaid by Aug 27, 2027, it lapses early.
- 1 fee due Mar 24, 2027The maintenance fee for Methods of Screening, Selecting, and Identifying Cytotoxic Recombinant Polypeptides Based on an Interim Diminution of Ribotoxicity (US 10,421,958) comes due Mar 24, 2027. Unpaid by Sep 24, 2027, it lapses early.
- 1 fee due Apr 22, 2027The maintenance fee for CD20-Binding Immunotoxins for Inducing Cellular Internalization and Methods Using Same (US 10,450,354) comes due Apr 22, 2027. Unpaid by Oct 22, 2027, it lapses early.
- 1 fee due Jul 2, 2027The maintenance fee for Shiga Toxin a Subunit Effector Polypeptides, Shiga Toxin Effector Scaffolds, and Cell-Targeting Molecules for Site-Specific Conjugation (US 11,857,628) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 1 fee due Sep 5, 2027The maintenance fee for PD-L1-BINDING Molecules Comprising Shiga Toxin a Subunit Scaffolds (US 11,918,649) comes due Sep 5, 2027. Unpaid by Mar 6, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,765,690 | Treatment of Cancer with Glufosfamide in Patients Not Receiving Insulin Therapy In force · High confidence | In force | High confidence | |
| US 10,815,469 | Cell-Targeting Molecules Comprising Protease-Cleavage Resistant, Shiga Toxin A Subunit Effector Polypeptides and Carboxy-Terminal Moieties In force · High confidence | In force | High confidence | |
| US 12,065,469 | De-Immunized Shiga Toxin a Subunit Effector Polypeptides for Applications in Mammals In force · High confidence | In force | High confidence | |
| US 12,637,495 | De-Immunized Shiga Toxin a Subunit Effector Polypeptides for Applications in Mammals In force · Medium confidence | In force | Medium confidence | |
| US 10,421,958 | Methods of Screening, Selecting, and Identifying Cytotoxic Recombinant Polypeptides Based on an Interim Diminution of Ribotoxicity In force · High confidence | In force | High confidence | |
| US 10,450,354 | CD20-Binding Immunotoxins for Inducing Cellular Internalization and Methods Using Same In force · High confidence | In force | High confidence | |
| US 12,037,367 | MHC Class I Epitope Delivering Polypeptides In force · High confidence | In force | High confidence | |
| US 10,392,425 | Multivalent CD20-Binding Molecules Comprising Shiga Toxin a Subunit Effector Regions and Enriched Compositions Thereof In force · High confidence | In force | High confidence | |
| US 11,365,223 | De-Immunized, Shiga Toxin a Subunit Scaffolds and Cell-Targeting Molecules Comprising the Same In force · Medium confidence | In force | Medium confidence | |
| US 11,389,542 | Shiga Toxin a Subunit Effector Polypeptides, Shiga Toxin Effector Scaffolds, and Cell-Targeting Molecules for Site-Specific Conjugation In force · Low confidence | In force | Low confidence |
Also on record, not counted in the 16: 11 patents in force now held by others · 9 lapsed for an unpaid fee · 6 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
4 pending · 20 abandoned · 10 no status recorded